These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 16048908)

  • 21. Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction.
    Warburton C; Dragowska WH; Gelmon K; Chia S; Yan H; Masin D; Denyssevych T; Wallis AE; Bally MB
    Clin Cancer Res; 2004 Apr; 10(7):2512-24. PubMed ID: 15073131
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting fatty acid synthase: potential for therapeutic intervention in her-2/neu-overexpressing breast cancer.
    Menendez JA; Lupu R; Colomer R
    Drug News Perspect; 2005; 18(6):375-85. PubMed ID: 16247515
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy.
    Pectasides D; Gaglia A; Arapantoni-Dadioti P; Bobota A; Valavanis C; Kostopoulou V; Mylonakis N; Karabelis A; Pectasides M; Economopoulos T
    Anticancer Res; 2006; 26(1B):647-53. PubMed ID: 16739334
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proteomic profiling and interactome analysis of ER-positive/HER2/neu negative invasive ductal carcinoma of the breast: towards proteomics biomarkers.
    Korwar AM; Bhonsle HS; Ghole VS; Gawai KR; Koppikar CB; Kulkarni MJ
    OMICS; 2013 Jan; 17(1):27-40. PubMed ID: 23301641
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selection of HER-2/neu-positive tumor cells in early stage cervical cancer: implications for Herceptin-mediated therapy.
    Bellone S; Palmieri M; Gokden M; Joshua J; Roman JJ; Pecorelli S; Cannon MJ; Santin AD
    Gynecol Oncol; 2003 Oct; 91(1):231-40. PubMed ID: 14529687
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 3, 3'-Diindolylmethane enhances the effectiveness of herceptin against HER-2/neu-expressing breast cancer cells.
    Ahmad A; Ali S; Ahmed A; Ali AS; Raz A; Sakr WA; Rahman KM
    PLoS One; 2013; 8(1):e54657. PubMed ID: 23372748
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of HER-2/neu overexpression and/or gene amplification in breast carcinomas: should in situ hybridization be the method of choice?
    Sauer T; Wiedswang G; Boudjema G; Christensen H; Karesen R
    APMIS; 2003 Mar; 111(3):444-50. PubMed ID: 12752225
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vincristine regulates the phosphorylation of the antiapoptotic protein HSP27 in breast cancer cells.
    Casado P; Zuazua-Villar P; del Valle E; Martínez-Campa C; Lazo PS; Ramos S
    Cancer Lett; 2007 Mar; 247(2):273-82. PubMed ID: 16843591
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overexpression of HER-2/neu in uterine serous papillary cancer.
    Santin AD; Bellone S; Gokden M; Palmieri M; Dunn D; Agha J; Roman JJ; Hutchins L; Pecorelli S; O'Brien T; Cannon MJ; Parham GP
    Clin Cancer Res; 2002 May; 8(5):1271-9. PubMed ID: 12006548
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New insights into anti-HER-2 receptor monoclonal antibody research.
    Kumar R; Mandal M; Vadlamudi R
    Semin Oncol; 2000 Dec; 27(6 Suppl 11):84-91; discussion 92-100. PubMed ID: 11236033
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HER2 (erbB-2)-targeted effects of the omega-3 polyunsaturated fatty acid, alpha-linolenic acid (ALA; 18:3n-3), in breast cancer cells: the "fat features" of the "Mediterranean diet" as an "anti-HER2 cocktail".
    Menéndez JA; Vázquez-Martín A; Ropero S; Colomer R; Lupu R
    Clin Transl Oncol; 2006 Nov; 8(11):812-20. PubMed ID: 17134970
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
    Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
    Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of HSP27 as a potential tumor marker for colorectal cancer by the two-dimensional polyacrylamide gel electrophoresis.
    Liu W; Ma Y; Huang L; Peng J; Zhang P; Zhang H; Chen J; Qin H
    Mol Biol Rep; 2010 Oct; 37(7):3207-16. PubMed ID: 19842058
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Upregulated HSP27 in human breast cancer cells reduces Herceptin susceptibility by increasing Her2 protein stability.
    Kang SH; Kang KW; Kim KH; Kwon B; Kim SK; Lee HY; Kong SY; Lee ES; Jang SG; Yoo BC
    BMC Cancer; 2008 Oct; 8():286. PubMed ID: 18834540
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients.
    Konecny GE; Meng YG; Untch M; Wang HJ; Bauerfeind I; Epstein M; Stieber P; Vernes JM; Gutierrez J; Hong K; Beryt M; Hepp H; Slamon DJ; Pegram MD
    Clin Cancer Res; 2004 Mar; 10(5):1706-16. PubMed ID: 15014023
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer.
    Konecny G; Untch M; Arboleda J; Wilson C; Kahlert S; Boettcher B; Felber M; Beryt M; Lude S; Hepp H; Slamon D; Pegram M
    Clin Cancer Res; 2001 Aug; 7(8):2448-57. PubMed ID: 11489825
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HER-2/neu expression in archival non-small cell lung carcinomas using FDA-approved Hercep test.
    Scheurle D; Jahanzeb M; Aronsohn RS; Watzek L; Narayanan R
    Anticancer Res; 2000; 20(3B):2091-6. PubMed ID: 10928158
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of proteomic signatures associated with lung cancer and COPD.
    Pastor MD; Nogal A; Molina-Pinelo S; Meléndez R; Salinas A; González De la Peña M; Martín-Juan J; Corral J; García-Carbonero R; Carnero A; Paz-Ares L
    J Proteomics; 2013 Aug; 89():227-37. PubMed ID: 23665002
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantitative proteomic analysis of HER2 normal and overexpressing MCF-7 breast cancer cells revealed proteomic changes accompanied with HER2 gene amplification.
    Tang Y; Mackey J; Lai R; Ghosh S; Santos C; Graham K; Damaraju S; Pasdar M; Li L
    J Proteomics; 2013 Oct; 91():200-9. PubMed ID: 23851309
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells.
    Menendez JA; Vellon L; Mehmi I; Oza BP; Ropero S; Colomer R; Lupu R
    Proc Natl Acad Sci U S A; 2004 Jul; 101(29):10715-20. PubMed ID: 15235125
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.